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Abstract Familial hypertrophic cardiomyopathy (FHC)
is an autosomal dominant disease, which in about 30% of
the patients is caused by missense mutations in one allele
of the b-myosin heavy chain (b-MHC) gene (MYH7). To
address potential molecular mechanisms underlying the
family-specific prognosis, we determined the relative
expression of mutant versus wild-type MYH7-mRNA. We
found a hitherto unknown mutation-dependent unequal
expression of mutant to wild-type MYH7-mRNA, which is
paralleled by similar unequal expression of b-MHC at the
protein level. Relative abundance of mutated versus wild-
type MYH7-mRNA was determined by a specific restriction
digest approach and by real-time PCR (RT-qPCR). Four-
teen samples from M. soleus and myocardium of 12
genotyped and clinically well-characterized FHC patients
were analyzed. The fraction of mutated MYH7-mRNA in
five patients with mutation R723G averaged to 66 and 68%
of total MYH7-mRNA in soleus and myocardium, respec-
tively. For mutations I736T, R719W and V606M, fractions
of mutated MYH7-mRNA in M. soleus were 39, 57 and
29%, respectively. For all mutations, unequal abundance
was similar at the protein level. Importantly, fractions of
mutated transcripts were comparable among siblings, in
younger relatives and unrelated carriers of the same
mutation. Hence, the extent of unequal expression of
mutated versus wild-type transcript and protein is charac-
teristic for each mutation, implying cis-acting regulatory
mechanisms. Bioinformatics suggest mRNA stability or
splicing effectors to be affected by certain mutations.
Intriguingly, we observed a correlation between disease
expression and fraction of mutated mRNA and protein.Electronic supplementary material The online version of this
article (doi:10.1007/s00395-011-0205-9) contains supplementary
material, which is available to authorized users.
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This strongly suggests that mutation-specific allelic
imbalance represents a new pathogenic factor for FHC.
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missense mutation  mRNA quantification
Introduction
Familial hypertrophic cardiomyopathy (FHC), the most
common genetic heart disease, is characterized by hyper-
trophy of the left ventricle and the inter-ventricular septum
(IVS), in the absence of overt etiological factors [23]. The
hypertrophy is often asymmetric and variable in severity
[16]. The prevalence of hypertrophic cardiomyopathy is 1
in 500; it affects individuals at every age [22]. FHC is often
associated with arrhythmias, syncope and progression to
heart failure or sudden cardiac death even at young age [23].
The genetically heterogeneous disease is transmitted as
an autosomal dominant trait [38]. Mutations in more than
18 genes, mostly encoding sarcomeric proteins, have been
linked to this disease in humans (Human Gene Mutation
Database at http://www.hgmd.cf.ac.uk/ac/index.php). To
date, approximately 30% of all genotyped cases were found
to be associated with missense mutations in the b-myosin
heavy chain (b-MHC) gene (MYH7) with chromosomal
localization 14q12 [34]. Notably, the human b-MHC iso-
form (UniProt ID P12883), besides being the principal
ventricular myosin isoform, is also expressed in the slow
skeletal muscle fibers, e.g., of musculus soleus [35].
Several mutations in the b-MHC are associated with early
onset and high incidence of sudden cardiac death, while
others have a less severe disease expression and outcome
[3]. This is usually explained by the type and location of the
mutations within the molecule and their different effects on
structure and function of the encoded protein [32]. Fur-
thermore, even among affected members of the same family,
variability in the clinical manifestations of FHC has been
observed, which points to additional risk factors [23].
A further mechanism for different clinical prognosis of
FHC-related mutations, however, could be the relative level
of mutated versus wild-type protein in patients with dif-
ferent mutations or even in patients with the same mutation.
Nearly all FHC patients are heterozygous for the respective
mutation, and both mutated and wild-type proteins are
assumed to be co-dominantly expressed from the corre-
sponding alleles. Equal proportions of the allelic messages
of the MYH7 gene and thus of the encoded protein are
assumed to be present in every muscle cell. Yet, a higher or
lower expression of the two allelic transcripts and proteins
resulting in a deviation from an expected 50-to-50 ratio,
known as allelic imbalance, has been shown previously for
expression of different genes in humans [8, 13, 48]. Thus,
allelic imbalance could well be quite significant for disease
expression in genetic disorders [29], as has been shown,
e.g., for hyperkalemic periodic paralysis in horses [50].
Evidence for allelic imbalance in FHC arises from our
previous work on functional effects of b-MHC missense
mutations. Since model systems of FHC often do not reveal
the same mutation effect as it may occur in humans [19, 25],
we study these mutations in M. soleus fibers and ventricular
biopsies of FHC patients. In muscle fibers from individuals
who were essentially asymptomatic but carried b-MHC
mutations G584R or V606M, respectively, we did not detect
any effects on sarcomere function. The fraction of mutated
b-MHC for mutations V606M and G584R was only 12 and
23% of the total b-MHC in the sarcomeres, respectively
[26]. This raised several questions: (1) Is the deviation from
the expected 50-to-50 ratio of wild-type versus mutated
myosin at the protein level paralleled by similar changes at
the mRNA level due to allelic imbalance? (2) Is an unequal
ratio of mutant versus wild-type protein and mRNA a
common feature in FHC caused by myosin mutations and
how is it correlated to the severity of the disease?
In the present study, we addressed these questions by
measuring the relative abundance of mutated and wild-type
MYH7-mRNA (RefSeq accession NM_000257) as well as
of the encoded protein for several different mutations in M.
soleus and cardiac muscle biopsies of FHC patients with
different disease severity. Wild-type and mutated MYH7-
mRNAs are co-expressed in the same cells/muscle fibers
and therefore are subjected to identical conditions. Thus,
variations due to confounding factors such as environ-
mental influences and drugs, of hormones, or differences in
tissue sampling or experimental procedures could be min-
imized. For all five MYH7 missense mutations studied, we
found a deviation from the usually expected equimolar
ratio of wild-type versus mutated b-MHC. The deviation
was very similar at the protein- and mRNA level and was
identical in myocardial tissue and M. soleus. Most inter-
estingly, the unequal abundance appears to be directly
related to the particular missense mutation, because it is
found to be essentially the same in all carriers of a given
mutation, including relatives of different generations and
unrelated individuals. Our results suggest that unequal
allelic expression of b-MHC contributes to the complex
phenotype of FHC.
Materials and methods
Patients and muscle biopsies
The present study was performed on muscle biopsies from
individuals previously characterized clinically as FHC
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patients and genetically as carriers of point mutations in the
b-MHC head domain. All patients were heterozygous for
the mutations they carried. In Table 1, clinical details
available to us and the age of all patients at the time of
biopsy are given.
For all patients, FHC features were evaluated on the
basis of medical history, physical examination, two-
dimensional and M-mode echocardiography, and 12-lead
electrocardiogram (ECG). Criteria for FHC were hyper-
trophy of the left ventricular wall, interventricular septal
thickness (IVS) C13 mm in the absence of other known
causes of hypertrophy and major ECG abnormalities like
negative T-waves, pathological Q-waves, or heart blocks.
Clinical records and family history of disease-related
deaths and age at death were used for assessment of life
expectancy with a given mutation (Table 1).
Mutation R723G: We obtained M. soleus tissue from
FHC patients of three families with this mutation [11].
Biopsies were from two brothers (H27, Family 26, II-5; and
H28, Family 26, II-2) and from a younger patient of the
same family (H71, Family 26, III-5). Both brothers had
received an ICD after syncopal episodes; H71 at the time of
biopsy was still NYHA class I. A soleus biopsy was
obtained from a younger patient of a third, unrelated family
(H72, Family 157, III-2) who had received an ICD. Left
ventricular tissue was available from patient H27 and an
unrelated female patient (H29, Family 11, III-8). Mutation
R719W: We obtained soleus tissue from a British female
(H13; [2]). After cardiac arrest and resuscitation, she had
received an ICD. Mutation V606M: Soleus biopsies were
available from a British individual (H5; [45]) and from an
unrelated American individual (H6; [12]. Mutation I736T:
We obtained soleus biopsies from three siblings of a
Kyrgyz family (Caucasian origin; [30]), one male (H18,
Family A, II-2) and two females (H19, Family A, II-4 and
H20, Family A, II-7) with moderate left ventricular and
septal hypertrophy (14, 18, 17 mm, for H18, H19 and H20,
respectively) and pathological ECGs. Mutation G584R:
The biopsy was from a young British male [45]. This
patient’s tissue underwent relative quantification of muta-
ted protein only. Controls: Soleus biopsies of several
healthy individuals, i.e., volunteers without any known
impairment of cardiac function. Detailed information on
sample preparation is given in Online Resource and [15].
Inclusion criteria for FHC of the individual patients can be
obtained from the respective references.
Written, informed consent was obtained from all indi-
viduals according to approved Ethics Committee protocols
of Hannover Medical School (protocols no. 2228 and no.
2729), of Hospital Clinic, Barcelona and of St. Georges
Hospital, London. The investigations conformed to the
principles of the Declaration of Helsinki [46].
RNA isolation, synthesis of sscDNA and PCR
For mutations I736T, R719W and V606M, total RNA was
isolated from approximately 3 mg pieces of frozen muscle
using Trizol (GIBCO, Karlsruhe, Germany). Isolated RNA
was reverse transcribed into cDNA (SuperScript First-
Strand Synthesis System for RT-PCR, GIBCO, Karlsruhe,
Germany). For mutation R723G, the RNA isolation from
both myocardium and soleus muscle, and the cDNA syn-
thesis steps were performed using cells-to-cDNA kit
(Ambion, Darmstadt, Germany). For reverse transcription,
an MYH7-specific primer RTR719W was used for all
samples. Amplification of regions of cDNA encompassing
the mutation site was performed using mutation-specific
primers (Online Resource). For mutations R719W, I736T
and V606M, the PCR reaction was performed by 1 min of
initial denaturation at 94C, 22–25 cycles of 30 s at 94C,
3 min at 68C and a final elongation for 3 min at 68C. For
mutation R723G, the reaction was performed using Hot-
StarTaq DNA Polymerase (Qiagen, Hilden, Germany).
Cycling included initial activation of the enzyme for
15 min at 95C, 35 cycles of 95C for 1 min, 68C for
30 s, 72C for 2.5 min and a final extension at 72C
for 5 min. Control reactions without mRNA, without reverse
transcriptase and without cDNA template, were run during
cDNA synthesis and PCR, respectively, to rule out con-
tamination or genomic DNA as a source of positive signals.
Reconditioning PCR
To avoid errors from heteroduplex formation at high cycle
numbers, we performed a reconditioning PCR [4, 41]. The
PCR product of up to 35 cycles was used at a final dilution
of 1:100 and was run in several parallel PCR reactions up
to a low cycle number in the exponential range (Fig. 1b).
Prior to the restriction digest, the products of the parallel
reactions were pooled and precipitated overnight by addi-
tion of 3 M sodium acetate to a final concentration of
200 mM plus addition of three volumes of absolute alco-
hol. For precipitation, the sample was kept at -80C.
Restriction digests
To discriminate between products from wild-type versus
mutated mRNA, the PCR products were digested with the
following restriction enzymes, according to the manufac-
turers’ recommendations: Nde II (Promega, Mannheim,
Germany) for R723G, MspI (New England Biolabs,
Frankfurt, Germany) for R719W, Hpy8I (Fermentas,
St. Leon-Rot, Germany) for I736T and Nla III (New England
Biolabs, Frankfurt, Germany) for V606M. The enzymes
were selected such that one cleavage site in the PCR product
Basic Res Cardiol (2011) 106:1041–1055 1043
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was specific for either the mutated or wild-type sequence
(for detailed description, see Online Resource).
Allele-specific relative quantification of RNA
transcripts
The DNA fragments generated by the restriction digests
were separated on 2.5 or 3.5% EtBr-agarose gels, using an
agarose for high-resolution separation of small DNA
molecules (Metaphor agarose, Cambrex Bio Science,
Rockland, USA; NuSieve agarose, Biozym, Oldendorf,
Germany). Since the intensities of EtBr-stained DNA
bands correlate with the total number of base pairs in the
respective bands, for quantification of relative transcript
levels we used the intensity of EtBr staining of the digested
PCR products (for details and controls, see Online
Resource). The integrated intensities of the individual
bands were obtained by curve fitting of the intensity pro-
files of the lanes using the software OriginTM (MicrocalTM
Software, Northampton, USA). Because we aimed at a
relative measure of transcripts from the two alleles in the
same sample, normalization to a reference housekeeping
gene was not required.
Control experiments for the relative mRNA
quantifications with known plasmid mixtures
Reconstitution experiments were used to test the linearity
and accuracy of the mRNA quantification method over
essentially the whole range of variations in allele ratio. The
wild-type and mutant MYH7 sequences that correspond to
the PCR products of each mutation were cloned into
plasmid pGA4 (Geneart, Regensburg, Germany) (R723G),
vector pMX (I736T and V606M) or vector pMA-T
(R719W) using the KpnI and SacI restriction sites. Several
defined mixtures of the respective wild-type and mutated
constructs ranging from 0 to 100% were applied to muta-
tion-specific PCR and subsequently quantified as described
for the patient samples.
Assessment of heteroduplex formation
The 125-bp fragment of the restriction digest of a 35-cycle
PCR product with mutation R723G was used to estimate
the fraction of heteroduplexes, which may form at high
cycle numbers (Fig. 1a, lower panels). The 125-bp band
was excised from the agarose gel and the DNA was
Fig. 1 Experimental approach to minimize heteroduplex formation.
a Schematic representation of restriction fragments produced by Nde
II digestion of wild-type and mutated homoduplexes for mutation
R723G (upper panels). Formation of heteroduplexes (lower two
panels) generates one refractory restriction site (gray arrows), thus
producing the 125-bp fragment from both strands of the heterodu-
plexes. b For reconditioning PCR, after 35 PCR cycles 1:100 dilutions
of the product were subjected to another PCR and quantified after
each cycle. The reaction was exponential until the seventh cycle.
IOD, integrated optical density (SD from densitometric analysis at
different exposure times). c 3.5% agarose gel with restriction digests
of PCR products of a sample from the left ventricular lateral wall of a
patient heterozygous for mutation R723G. The 35-bp fragment is not
seen due to its small size. Cleavage of the reconditioning PCR
products of three, four, five or six cycles (lanes 3C–6C) yielded
mutated MYH7-mRNA fractions of 73, 82, 77 and 75%, respectively
(on average 74 ± 8% in this muscle sample). There was no indication
for heteroduplex-induced increase of mutated MYH7-mRNA at
increasing cycle numbers. Lanes 1–3 12, 15 and 18 ll of equimolar
DNA standard; B blank; U undigested PCR product
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purified using gel purification kit (Qiagen, Hilden, Ger-
many). The fragments were cloned into a pAlli10 vector
using the Alligator Cloning Kit (Trenzyme, Konstanz,
Germany) and sequenced at GATC (Konstanz, Germany)
in the forward as well as reverse orientations to determine
the sequences of both strands.
Allele-specific real-time PCR (RT-qPCR) assay
As an alternative approach to determine relative levels of
wild-type and mutated MYH7-mRNA in cardiac biopsies
with mutation R723G (patient H27, left and right ventric-
ular wall), allele-specific RT-qPCR was performed. The
hybridization probes specific for the detection of either
wild-type or R723G-mutant alleles of MYH7 were fluo-
rescently labeled at the 50-ends with VIC and 6-FAM,
respectively, and with a non-fluorescent quencher at the
3’end (Assays-by-Design Service, Applied Biosystems,
Foster City, CA) (Online Resource). Amplification was
performed using identical primers for both alleles [47],
excluding bias caused by unequal amplification efficacy.
For experimental conditions and analysis, see Online
Resource. Detection of the two alleles occurred in a single-
tube analysis. Relative quantification was performed
according to the delta-CT method [31].
Relative quantification of wild-type versus mutated
protein
The relative abundance of wild-type and mutated b-MHC
was determined by liquid chromatography/electrospray-
ionization mass-spectrometry as described in detail previ-
ously [5]. Quantification is based on myosin extraction and
generation of peptides using endoproteinase Lys-C (Roche,
Mannheim, Germany). Peptides with mutant and wild-type
sequences and an isotopically enriched (13C, 15N) leucine
in each sequence (Coring System Diagnostix, Gernsheim,
Germany) served as internal standards. Relative quantifi-
cation of wild-type and mutated b-myosin was based on
peak areas obtained by MS for the stable isotope-labeled
and for the native peptides. Alternatively, for some samples
the peptides generated by Lys-C were quantified using our
previously published method of HPLC and MS coupled to
capillary zone electrophoresis [26].
Statistics
Results are presented as mean ± SD. For each individual,
mRNA and protein quantifications were based on at least
three different muscle biopsy pieces. Quantification
occurred by repeated PCR reactions [given as n indepen-
dent experiments (assays) in results], each of which was
analyzed in two to four lanes on each gel. For one patient
with mutation V606M of American origin, only one sample
of soleus muscle tissue was available for analysis. Statis-
tical significance of deviations from a 50-to-50 ratio of
mutant versus wild-type mRNA and protein, or differences
between two samples, was tested using one-sample t test
and two-sample unpaired t test, respectively. p values
\0.05 were considered to be significant.
Results
Reconditioning PCR for relative quantification
of wild-type and mutant MYH7-mRNA
To quantify the ratio of wild-type and mutant MYH7-
mRNA in the samples of human FHC patients, we per-
formed a highly specific reverse transcriptase-polymerase
chain reaction followed by mutation-specific restriction
analysis. The MYH7-mRNA was reverse transcribed using
a MYH7-specific primer for all analyzed mutations. For the
restriction analysis, cDNA encompassing the respective
mutation site was amplified using mutation-specific prim-
ers (Online Resource). Mutant and wild-type fragments
were subsequently cleaved by DNA-restriction enzymes
specific for restriction sites either generated (I736T,
c.2313T[C; V606M, c.1922G[A) or disrupted (R719W,
c.2261C[T) by the respective mutations. Mutation R723G
(c.2273C[G) does not lead to a changed restriction site.
Here, a mutagenic forward primer was used to create an
additional cleavage site for Nde II in the wild-type PCR
product only (Online Resource). The mutation-specific
DNA-restriction fragments were then quantified to deter-
mine the ratio of wild-type and mutated MYH7-mRNA in
each sample.
To obtain sufficient PCR product for the subsequent
restriction digest analysis, up to 35 cycles had been nec-
essary. At such high cycle numbers, formation of hetero-
duplexes between wild-type and mutated strands in the
PCR product is possible (Fig. 1a, lower panels). Sequence
analysis of 105 cloned mutation-specific 125-bp fragments
showed only two fragments to contain sequences that result
from formation of heteroduplexes. Thus, we could assert
with 95% confidence that the heteroduplexes formed at 35
cycles were \10%.
Yet, to minimize heteroduplex formation, we used a
reconditioning PCR method for most quantifications [4, 41].
After 35 cycles, the PCR product was diluted 100-fold
and submitted to about ten parallel PCR reactions. Starting
from cycle 4, the reaction was stopped for one aliquot at
each cycle. Aliquots were run on a gel and relatively
quantified (Fig. 1b). The exponential range where the slope
of the regression curve is close to two was limited to about
the seventh cycle. Analysis of the ratio of mutation to wild-
1046 Basic Res Cardiol (2011) 106:1041–1055
123
type specific restriction fragments in four subsequent PCR
cycles from the exponential range revealed comparable
ratios from cycles 3 to 6 (Fig. 1c). This indicates that our
results are not influenced by a bias caused by heteroduplex
formation, which would lead to an increase of the unc-
leaved 125-bp fragment (Fig. 1a, lower panels). For each
mutation, the exponential range of the reconditioning PCR
was determined and the number of necessary aliquots for
pooling was set by the signal intensities needed for quan-
tification on the gels (data not shown).
Relative quantification of mutant versus wild type
in defined mixtures of plasmids reveals accuracy
of method
To test the sensitivity of our method for mRNA quantifi-
cation and to verify the analysis procedure, we examined
whether the observed ratio of mutated versus wild-type
fragments in reconstituted heterozygous samples reflects
the selected input ratio. We generated standard vectors that
contained the PCR fragments for each mutation and the
respective wild-type DNA (Online Resource). Defined
mixtures of mutated and wild-type vectors in the ratios
0:100, 20:80, 40:60, 50:50, 70:30 and 90:10 100:0 were
subjected to reconditioning PCR. After restriction digestion
of the PCR products, gels were loaded such that the bands
were in the linear intensity range of EtBr fluorescence
(Fig. 2a; see also Online Resource).
As shown exemplarily for mutation R723G, the frac-
tions of mutant DNA obtained from the above mentioned
mixtures of plasmids were 0, 23.3 ± 1.5, 39.3 ± 3.7,
49 ± 5.2, 68 ± 5.1, 86.5 ± 3.5 and 100%, respectively
(Fig. 2b; n = 3). Thus, the mixed allelic templates were
amplified and detected essentially in direct proportion to
the stoichiometric fraction of each template over a wide
range of mutant to wild-type template ratios. In addition,
the absence of the mutation-specific 125-bp fragment in the
0:100 mixture (Fig. 2a; lane 8) confirms complete diges-
tion at all restriction sites. Similar results were also
obtained with plasmid mixtures for the other mutants
I736T, V606M and R719W (Online Resource).
Unequal allelic expression of wild-type and mutated
MYH7-mRNA
The established assays were used to quantify the relative
expression levels of wild-type and mutated MYH7-mRNA
isoforms in M. soleus biopsies from FHC patients with
mutations R723G, I736T, R719W and V606M (Table 1;
see also Online Resource).
For mutation R723G, the fraction of mutated transcript
was determined from the ratio of IOD/bp values of the
Fig. 2 Relative quantification of R723G mutated and wild-type
sequences in defined plasmid mixtures and biopsies. a Restriction
fragments of the 281-bp PCR product generated from defined
mixtures of R723G-mutant and wild-type plasmid (Lanes 2–8). Lane
L, equimolar DNA standard; lane B, blank; lane 1, undigested
product. The increasing ratio (indicated above lanes) of mutant versus
wild-type sequence resulted in brighter bands of 125 bp and weaker
bands of 90 bp. b Input versus experimentally determined mutation-
specific DNA in plasmid mixtures (n = 3 assays). The dashed line
indicates the expected values. c Representative gel with the
undigested 281-bp PCR product (lane 1) and restriction fragments
after reconditioning PCR for three, four, five and six cycles (lanes
2–5) from a M. soleus sample of patient H27. L, equimolar DNA
standard; B, blank. d Fraction of mutated mRNA in the left
ventricular wall (light columns) and M. soleus (dark columns) of
patients from three unrelated families with mutation R723G. The age
(years) of patients at M. soleus biopsy is indicated; *patient H27 was
transplanted & 1 year after soleus biopsy)
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mutation-specific 125-bp fragment versus the 156-bp
fragment. Analysis of four patients revealed fractions of
mutated MYH7-mRNA of 62 ± 3.5% (H28, n = 4 assays),
66.1 ± 4.3% (H72, n = 4 assays), 66.4 ± 6.9% (H27,
n = 5 assays) and 69.6 ± 7.7% (H71, n = 4 assays) of the
total MYH7-mRNA (Fig. 2d; Table 1). The expression
level of mutated MYH7-mRNA among all patients with this
mutation available to us was not significantly different
(p C 0.05), but only for H28 it was slightly lower
(p = 0.05). This indicates that the expression of the
mutated MYH7-mRNA was very similar even among
patients of different generations and from unrelated
families.
For relative quantification of mutant and wild-type
MYH7-mRNA with mutation I736T, M. soleus biopsies of
three siblings were available to us. The fraction of mutated
MYH7 transcript was calculated from the IOD/bp value of
the mutation-specific 205-bp fragments and the wild-type
specific 354-bp fragments (Online Resource). The fraction
of mutated MYH7-mRNA was 37.6 ± 4.2% (n = 8
assays), 39.1 ± 4.1% (n = 9 assays) and 38.6 ± 5.3%
(n = 9 assays) of total MYH7-mRNA for FHC patients
H18, H19 and H20, respectively.
For mutation V606M, the fraction of mutated MYH7-
mRNA in the biopsies was calculated based on the IOD/bp
values of the mutant-specific 180-bp fragment versus the
total IOD/bp value of wild-type specific 267-bp fragment
plus the mutant-specific 180-bp fragment (Online
Resource). This yielded on average 28 ± 6% MYH7-
mRNA of total MYH7-mRNA with mutation V606M
(n = 12 assays).
For the patient with mutation R719W, the fraction of
mutated MYH7-mRNA was 57.1 ± 5.4% of the total
MYH7-mRNA (n = 9 assays), indicating a small yet sig-
nificant (p \ 0.01) deviation from equal abundance of
wild-type and mutated transcript (Online Resource). The
fraction of mutated MYH7-mRNA was calculated based on
the IOD/bp values of the mutation-specific 269-bp frag-
ment versus the average of the two wild-type specific
fragments of 146 and 123 bp.
Same deviation from the equimolar ratio
in myocardium and slow skeletal muscle for mutation
R723G
Samples of ventricular tissue of two members of two
unrelated Spanish families with mutation R723G were
available to us. One patient (H27) underwent heart trans-
plantation about 1 year after the M. soleus biopsy was
taken. The other myocardial sample was of a transplanted
female patient (H29) of an unrelated family. In the left
ventricular wall of H27 and H29, the fraction of mutated
transcript was 69 ± 8.8% (n = 20 assays) and 67.2 ± 5%
(n = 9 assays) of total MYH7-mRNA, respectively
(Table 1). Hence, at least for R723G patients, the deviation
from the equimolar ratio of wild-type versus mutant
MYH7-mRNA and thus the fraction of mutated transcript is
essentially the same in skeletal and ventricular biopsies
(Fig. 2d).
Validation of allelic imbalance for mutation R723G
by allele-specific real-time PCR (RT-qPCR)
To corroborate the results of the restriction digest
approach, we performed allele-specific RT-qPCR from left
and right ventricular biopsies of patient H27 with mutation
R723G. Both alleles were analyzed in the same reaction
using mutation or wild-type specific probes, respectively,
which were labeled by two distinct dyes (Online Resource).
Using the delta-CT method, we found on average
61.7 ± 8.9% (n = 8 assays) and 64 ± 13.3% (n = 18
samples in two assays) of mutated transcript in the left and
right ventricular muscle, respectively. Both values are well
consistent with data obtained on the same samples with the
restriction digest approach (Fig. 3; [7]).
Corresponding deviations from the equimolar ratio
for b-MHC mutations also at the protein level
The fraction of wild-type and mutated b-myosin was
determined after myosin extraction and enzymatic cleavage
Fig. 3 Allele-specific RT-qPCR for quantification of mutated versus
wild-type MYH7-mRNA in myocardium. For RT-qPCR, mRNA from
cardiac tissue samples was reverse transcribed using a MYH7-specific
RT-primer. Subsequent comparative quantitative PCR was accom-
plished using identical primers and differently labeled mutation or
wild-type specific probes in one reaction tube (Online Resource).
RT-qPCR data are shown in comparison to data from restriction
digest approach performed on the same cardiac samples from left
ventricular (LV) anterior wall and right ventricular (RV) wall of H27
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using liquid chromatography/electrospray-ionization mass-
spectrometry (LC/ESI-MS) or LC/MS in combination with
capillary zone electrophoresis, which we previously
developed [5, 26]. Figure 4 shows ESI-MS spectra of Lys-
C digested native b-MHC peptides from a patient carrying
mutation R723G and the corresponding synthetic stable-
isotope labeled internal standard (IS) peptides. Equal
amounts of mutated and wild-type IS-peptides yielded
slightly different integrated peak areas (Fig. 4a, b). This
most likely is due to different competition for ionization of
IS-peptides with peptides of the Lys-C digest, and is taken
into account for quantification (Fig. 4c, d).
b-MHC quantifications in M. soleus biopsies (Table 1)
of two patients with mutation R723G (H27 and H28)
yielded 61.6 ± 6% (n = 36 peptide samples) and
62.4 ± 7% (n = 31 peptide samples) mutated myosin of
total b-MHC, respectively [5]. Preliminary b-MHC quan-
tification of cardiac samples from patient H27 yielded
essentially the same fraction of 62.7 ± 11% (n = 2 pep-
tide samples) mutated myosin of total myosin as found in
M. soleus. The fraction of mutated myosin in the soleus
muscle biopsy of the patient with mutation R719W was
54 ± 7% (n = 4 muscle samples). The siblings with
mutation I736T had 43 ± 13, 33 ± 3 and 42 ± 7%
(n = 4–7 muscle samples) mutated myosin of total b-MHC
in the sarcomeres of their M. soleus, respectively. The
American patient with mutation V606M had 13 ± 2%
(n = 3 peptide samples of 1 muscle sample) mutated
myosin of total b-MHC. As previously published, the
British patient with V606M had 12 ± 6% and the patient
with mutation G584R had 23 ± 1% mutated myosin of
total b-MHC, respectively [26].
Interestingly, the mRNA levels were similar to the
corresponding protein levels for mutations R723G, R719G
and I736T (Fig. 5), as determined by non-significant
deviations (Student’s t test, p [ 0.5). Note that the devia-
tion between protein and mRNA quantification for one
patient with mutation V606M might be because mRNA
analysis for this specific patient was carried out on tissue
initially frozen for histology. Nevertheless, both the frac-
tion of mutated mRNA and protein for this mutation are
significantly below 50%.
Discussion
Levels of mutated versus wild-type MYH7-mRNA
and protein deviate from an equimolar ratio
In general, both alleles of autosomal genes are assumed to
be co-dominantly expressed. Thus, in a tissue sample
carrying a heterozygous missense mutation, an equimolar
Fig. 4 MS spectra of native and
synthetic b-MHC wild-type
peptides and of peptides with
mutation R723G. The Lys-C
digest fraction of b-myosin
containing native wild-type and
R723G-mutated peptides was
analyzed by nanoLC–ESI-MS
after adding equimolar amounts
of stable isotope-labeled
synthetic wild-type and mutant
internal standard peptides. The
traces represent ion signals of
the fivefold charged synthetic
mutant (a; m/z 764.1), synthetic
wild-type (b; m/z 783.9), native
mutant (c; m/z 763.1) and native
wild-type (d; m/z 782.8)
peptides. Note the quite large
difference in peak areas
between native wild-type and
mutated peptides mainly
representing the difference in
abundance of the two peptides
and thus of the two parent
proteins in the muscle sample
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ratio is expected for wild-type and mutated transcripts and
encoded proteins. Yet, assessment of these ratios of five
different FHC-causing b-myosin missense mutations
revealed an allelic imbalance at the mRNA as well as at
the protein level. The fraction of mutated MYH7-mRNA
and b-myosin ranges from less than 20–70%. Most
interestingly, these ratios seem to be characteristic for the
respective mutations, as shown for mutations V606M,
I736T and R723G. Further, they are identical for both
myocardium and skeletal muscle at least with mutation
R723G.
The finding that in all cases studied, the fraction of
mutated protein was essentially the same as the mRNA in
the same tissue indicates that at the translational level and
upon incorporation of protein into the sarcomere, no large
additional deviations arise, e.g., due to poor incorporation
or degradation of mutant b-myosin protein. It is unlikely
that missense mutations in MYH7 cause haploinsufficiency,
although relative quantification cannot fully exclude this. It
has been demonstrated that b-myosin with missense
mutations in the head domain is incorporated into the
sarcomeres of cardiac and slow-twitch skeletal muscles [5,
21, 26]. No alterations of sarcomeric structure, packing of
myofibrils or assembly of the thick filaments were found
[6, 17]. The mutations studied here rather act by inducing
functional changes of the acto-myosin interactions and,
therefore, of the whole sarcomere [15, 17, 36].
How may missense mutations affect steady-state
mRNA levels?
The data suggest that the deviation from the equimolar
ratio is an inherent property of each mutation itself. Allele-
specific expression of genes is mostly regulated by cis- or
trans-acting factors of either genetic or epigenetic origin.
To assess whether allelic imbalance may be due to auto-
somal imprinting or is independent of parental origin [33],
we analyzed the available family pedigrees of the different
patients. Since mutations R723G and V606M were passed
on through either the paternal or the maternal germ line,
imprinting is highly unlikely. For mutation I736T, the
genetic status of the parents is not known. The analysis of
the molecular mechanisms of imprinting renders this
probability rather unlikely. The altered efficiency of tran-
scription due to methylation of cytosines in the CpG
dinucleotide sequence provides an important mechanism of
sequence-dependent imprinting of genes [14]. However,
the two CpG-islands within the MYH7 gene (Accession
number NG_007884) at positions 15,421 to 15,723 and
20,455 to 20,682 (http://www.ebi.ac.uk/Tools/emboss/
cpgplot/) remain unaffected by each of the missense
mutations examined here and no additional CpG-island is
predicted to be created. However, it cannot fully be
excluded that a linked non-coding variant in cis causes the
allelic imbalance in individuals from apparently unrelated
families. Haplotype analysis of the three Spanish kindreds
with mutation R723G suggests a common founder muta-
tion [11]. For the unrelated patients with mutation V606M,
such analysis has not been reported.
Allele-specific expression of MYH7-mRNA due to sin-
gle nucleotide substitutions could be caused by alteration
of mRNA stability. One determinant of RNA-stability is its
secondary structure that can affect, e.g., the accessibility to
stability-regulating proteins or the recruitment into RNA-
induced silencing complexes (RISCs) [20]. We bioinfor-
matically examined the influence of each point mutation on
the secondary structure of the MYH7-mRNA using the
RNAfold program (http://www.rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi). Severe changes in the secondary struc-
ture for mutations V606M (c.1922G[A) and R723G
(c.2273C[G) (Fig. 6a) were identified, whereas mutations
R719W (c.2261 C[T) and I736T (c.2313 T[C) did not
alter the mRNA structure. These findings are a first hint
that structural changes induced by mutations V606M and
R723G may influence the MYH7-mRNA turnover and
thereby lead to different protein levels.
Allelic imbalance could also be caused by differential
splicing of the mutated allele. The splicing efficacy can be
affected either by the secondary structure of the transcript,
namely hairpin structures located close to exonic splicing
enhancers (ESE) or exonic splicing silencers (ESS) [18], or
Fig. 5 Fractions of mutated MYH7-mRNA and b-myosin for differ-
ent FHC mutations. The fractions of mutated mRNA (gray bars) and
protein (black bars) in M. soleus are summarized for mutations
V606M, I736T, R719W and R723G. Additionally, the R723G-
mutated mRNA fractions in myocardium and previously published
protein levels of mutations G584R and V606M [26] are depicted.
mRNA data shown here are from the restriction digest approach. All
data are also listed in Table 1. All mutations significantly deviate
from equal abundance of wild-type and mutated transcript with
similar deviations also at the protein level. Similar deviations of
mRNA and protein levels were found in M. soleus and myocardium
for mutation R723G (LV, left ventricle; RV, right ventricle). Note the
intra- and/or inter-familial similarity in mutated MYH7-mRNA/
protein expression for I736T, R723G and V606M
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by sequence motifs [9]. We thus examined the structure of
the pre-mRNA from exon 15 to 21, the region including
each analyzed mutation (Fig. 6b) and the effect of the
mutations on splicing regulatory motifs using the Human
Splicing Finder program (http://www.umd.be/HSF/) [9]
and the ESE Finder program (http://www.rulai.cshl.
edu/ESE; version 3.0).
Analysis of mutation V606M revealed the generation of
novel hairpin structures in exon 16 (Fig. 6b) and the dis-
ruption of ESE motifs. Such effects have been reported to
cause exon skipping [49]. Skipping of exon 16 in the
MYH7-mRNA would cause a premature stop-codon at
position 552 and thereby most likely lead to nonsense-
mediated decay (NMD) of the mutated allele. In contrast,
mutation I736T (c.2313 T[C) is predicted to strengthen an
existing ESE at position 2,308–2,315 (variation ?13.4%).
This could lead to the activation of a cryptic splice site and
thereby either to NMD or to the generation of mRNA that
is not detected by our assay and encodes for a non-func-
tional b-MHC.
Mutations R719W (c.2261C[T) and R723G
(c.2273C[G) lead to increased mutated mRNA- and pro-
tein fractions. The mechanisms underlying the regulation
of such hypermorphic mutations are poorly understood.
Fig. 6 Secondary structure of
MYH7 pre-mRNA and mature
mRNA. The RNAfold program
(minimum free energy) was
used to compare the secondary
structure of the MYH7 mRNA
of mutated and wild-type
isoforms. Mutations R719W
and I736T generate identical
structures as the wild-type
sequence and are therefore not
depicted. a Secondary mRNA
structures of wild-type
(NM_000257), mutation
V606M (c.1922G[A) and
mutation R723G (c.2273C[G).
b Secondary structure of the
pre-mRNA of wild-type exon
15 to exon 21 (position
6,992–10,380, NG_007884).
Enlarged boxes: sites of
structural alterations caused by
mutations V606M (c.1922G[A,
green arrow) and R723G
(c.2273C[G, red arrow). Blue
arrow in the wild-type
sequence: location of mutation
R719W that does not alter the
pre-mRNA structure
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Interestingly, both mutations are located in hairpin struc-
tures at intron–exon boundaries (Fig. 6b). Such mutations
have been reported to influence splicing efficacy [18, 39].
Therefore, one could speculate that a more efficient splic-
ing of the mutated as compared to the wild-type pre-mRNA
may lead to the different mRNA and protein levels. Further
studies will have to reveal whether changes in mRNA
stability, differential splicing or a linked cis-acting variant
could provide the underlying mechanisms of the observed
allelic imbalance.
Does the abundance of mutated protein contribute
to severity of the FHC phenotype?
Most interestingly, our results suggest that the abundance
of mutated mRNA and mutated protein is correlated with
the reported severity of the clinical outcome of FHC and
the extent of functional changes at the sarcomeric level
(Table 1). For nearly all of the mutations studied, a large
fraction of mutated transcript and protein correspond to a
severe long-term disease progression in the families and
pronounced effects on the function of the contractile
apparatus.
One very malignant mutation is R723G, where about 2/3
of total MYH7-mRNA and b-myosin are mutated. Patients
with this mutation have a chance of only about 18% to reach
the age of 50 years without a cardiac event and with NYHA
class II or better. Mean survival in the three families studied
by Enjuto et al. [11] was 51 years. Some patients with this
mutation develop severe heart failure in their forties or fifties
[11], which is generally found in a subgroup of FHC patients
[40]. Patient H27 in our study, as a typical example, initially
developed the classical clinical phenotype of FHC with
diastolic dysfunction and septal hypertrophy. This pheno-
type then progressed into LV dilatation and systolic heart
failure resulting in a heart transplant [7]. Interestingly, our
own preliminary analysis of phosphorylation of sarcomeric
proteins in cardiac tissue of patients H27 and H29 with
mutation R723G showed significantly reduced phosphory-
lation, as commonly found in heart failure. The typically
increased calcium sensitivity of cardiomyocytes from failing
hearts [42], however, was not seen. Instead, calcium sensi-
tivity was dominated by the mutation effect (own, unpub-
lished observations). In studies on M. soleus fibers from
patients H27 and H28, we previously observed a significant
reduction in calcium sensitivity due to mutation R723G [15].
A similar reduced calcium sensitivity was also found in M.
soleus fibers with mutation R719W (patient H13). Both
mutations, R723G and R719W, also caused a pronounced
increase in resistance to elastic deformation and substantial
increase in force generation of the mutated myosin heads
[15, 17, 36]. The large functional effects of mutation R719W
at the sarcomeric level correspond to the fairly high
expression level of 57% mutated MYH7-mRNA of total
MYH7-mRNA, and the high risk of sudden death with this
mutation [2]. Note that age-related penetrance of the disease
plays an important role as well. In patients with mutation
R723G, a malignant mutation appears benign at young age
(patients H71 and H72), while mutation R719W is already
very severe in young patients. Average life expectancy with
mutation R719W is 38 years [2]. In muscle tissue with
mutation I736T, only slightly more than 1/3 of total myosin
was mutated and only small effects of the mutation on the
contractile apparatus were observed [15, 36]. All three
patients harboring mutation I736T showed mild clinical
symptoms with a normal life expectancy [30]. Similarly, the
individual with mutation G584R (23% of mutated protein)
was essentially unaffected by the disease [2] and no func-
tional changes were detected at the sarcomeric level.
For mutation V606M, the correlation between expres-
sion level and severity is less clear. The low abundance of
mutated protein corresponds to the lack of functional
changes in the muscle fibers and to the benign course of the
disease in one of these individuals (H5) and in several
families with this mutation [44, 45]. Survival at 50 years of
age was 95%, which indicates nearly normal life expec-
tancy. However, despite the low fraction of myosin with
mutation V606M, the family of the other patient (H6) had a
malignant form of the disease based on the fact that four
out of eight HCM patients in the kindred studied died
prematurely of sudden cardiac death [12]. It is unclear
whether this is due to additional, as yet undetected etio-
logical factors. Alternatively, since in patient H6 not all
major candidate genes for mutations causing FHC have
been analyzed, an additional mutation in another sarcomere
gene contributing to disease severity cannot be excluded,
although only up to 5% of all FHC patients are double or
compound heterozygotes [34]. This holds also true for the
other patients in our study.
Nevertheless, the correlation between life expectancy or
severity of disease and expression level of mutated b-MHC
is an additional aspect in FHC genotype–phenotype cor-
relation and may represent a new prognostic parameter. In
the past, mutations that result in a change in charge of the
encoded amino acid have been correlated with a signifi-
cantly shorter life expectancy [2, 44]. In later studies, it
was suggested that the striking clinical and pathological
heterogeneity is at least partially a function of the affected
sarcomeric protein [10, 24]. For instance, families with
cardiac troponin-T mutations appeared to have a particu-
larly high risk of sudden cardiac death, while mutations in
cardiac myosin-binding protein C are characterized by a
benign course of the disease [27, 43]. Yet, the risk of
disease-related complications for each patient varies also
with modifying genes and lifestyle [1, 10, 37]. Our
observation that the relative abundance of mutated and
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wild-type protein correlates with disease severity at least
for mutations in the b-MHC could be a reason why in FHC
no strong genotype–phenotype correlation has been estab-
lished so far. Based on our functional studies on b-MHC
mutations, we hypothesize that the mechanism responsible
for the severe phenotype in patients with a large fraction of
mutated b-myosin is a functional imbalance among indi-
vidual cardiomyocytes because of unequal expression of
the mutant protein from cell to cell [15]. Functional
imbalances, e.g., in force generation, might represent a
unifying mechanism triggering a common pathological
pathway in FHC for different mutations, despite variable
primary functional effects [28, 37]. Further studies on more
FHC mutations, also in other sarcomeric proteins, are
necessary to corroborate the correlation between disease
severity and overall expression level of mutated protein.
In summary, relative quantification of wild-type and
mutated MYH7 transcript and protein in muscle tissue of
FHC patients shows that altered structure and function of
the protein most likely are not the only determinants of its
pathogenic effect. In addition, the sequence-specific
unequal abundance of mutated and wild-type protein may
contribute to the development of the complex phenotype in
FHC. It would be of high clinical interest to further
investigate (1) the mechanisms underlying the observed
allelic imbalance and (2) whether the fraction of mutated
transcript and protein is an indicator/determinant of prog-
nosis and survival for a given mutation and family also for
FHC mutations in other proteins.
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Supplementary Material  
 
Preparation of M. soleus and myocardial samples 
The M. soleus biopsies of FHC patients and control individuals were excised under local 
anaesthesia (cf. ethics statement in manuscript). All biopsies were approximately 10 x 10 x 
15 mm3. Immediately after surgery the biopsies were cooled, and small pieces were dissected 
from the biopsies and shock-frozen in liquid nitrogen for mRNA quantification. The method 
of sample preparation was the same for all biopsies taken, and was carried out each time by 
two of the authors (B.Br. and T.K.) at the respective hospitals in Barcelona, London or 
Hannover (for the Kyrgyz patients and for the controls). Only the sample of mutation V606M 
from the patient of American origin was taken by others in the United States and shock frozen 
in liquid nitrogen. In addition, the mRNA analysis of the V606M sample of British origin was 
performed using muscle tissue that had initially been prepared for cryo-sectioning and 
histological examination. Prior to shock-freezing in liquid nitrogen this muscle biopsy was 
mounted on cork using tissue freezing medium (Tissue-Tek, Sakura Finetek, Netherlands). 
This biopsy was stored at –80°C at all times except for cryo-sectioning, so that intact mRNA 
could be obtained. All the other samples for mRNA quantification were stored in liquid 
nitrogen until mRNA isolation.  
Samples of ventricular myocardium of patient H27 and H29 were obtained from the explanted 
hearts during heart transplantation. These samples were shock frozen immediately after 
dissection. Small pieces of tissue for mRNA quantification were obtained by crushing the 
tissue using a mortar and pestle cooled with liquid nitrogen. 
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Restriction analysis of MYH7 fragments of mutations V606M, R719W and I736T 
For each mutation we developed a specific restriction assay based on restriction sites either 
generated or disrupted by the respective mutation. The mutation- and wild-type-specific 
restriction fragments were subsequently analysed densitometrically and relatively quantified. 
Since the intensities of EtBr-stained DNA bands are expected to correlate with the amount of 
DNA (total number of bp) in the respective bands, for quantification of relative levels of 
transcript we used the intensity of EtBr staining of the digested PCR products [1]. Yet, for 
relative quantification of the different fragments it was necessary to ensure that the EtBr 
intensities of the relevant bands were all in the linear intensity range of the gel. Therefore, an 
equimolar DNA-standard (Low DNA Mass Ladder, Invitrogen AG, Basel, Switzerland) was 
also run on each gel parallel to the restriction digests (Fig. 1c). This ladder consists of six 
DNA fragments. The lengths of the three faster migrating fragments (400 bp, 200 bp and 100 
bp), relevant for our analysis, are in the ratio 4:2:1. To ensure this, on each gel the bands of at 
least three lanes of different volumes of equimolar DNA-standard were analyzed besides the 
bands of the restriction digests. Intensities of the individual bands of the equimolar DNA-
standards and of the restriction digests of amplified patient cDNA were obtained 
densitometrically using the Gel-Pro Analyzer software (MediaCybernetics, Bethesda, MD, 
USA) and TotalLab Software (Newcastle upon Tyne, Great Britain). A measure for the 
fragments in each band of equimolar ladder and restriction digests was obtained by 
calculating the ratio of the total integrated intensity of this band vs. the number of base pairs 
of the respective fragment (IOD/ bp). From the IOD/ bp values of the standard bands with 400 
bp, 200 bp and 100 bp we determined the linear intensity range of detection by EtBr of each 
gel. On the respective gel, only the lanes with restriction digest fragments in the linear 
intensity range were used for relative quantification.  
 
Mutation I736T 
The I736T (c.2313T>C) mutation is caused by a T to C transition in exon 20 of MYH7, which 
creates a cleavage site for Hpy8I that is absent in the wild-type sequence. However, to 
distinguish the wild-type fragment from undigested PCR products (Fig. S1), we introduced a 
cleavage site into the PCR product by using a mutagenic forward primer (Table S1). Cleavage 
of heterozygous 378 bp PCR products by Hpy8I generates fragments of 354 bp and 24 bp 
from the wild-type sequence and of 205 bp, 149 bp and 24 bp from the mutated sequence 
(Fig. S1b). For all three patients the fraction of mutated MYH7 transcript was calculated based 
on the IOD/ bp value of the 205 bp fragments of the mutated and the 354 bp fragments of the 
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wild-type, i.e., only the larger fragments were used. As an internal control for mutation I736T, 
we also calculated the ratio of the IOD/ bp values for the mutant fragments of 149 bp and 205 
bp. The ratio was 0.96±0.14, 1.01±0.09 and 0.99±0.07 for patients H18, H19 and H20, 
respectively. This indicates a rather small deviation from the expected ratio of 1.0 for these 
two fragments.  
To ensure that the efficiency of PCR amplification and digestion is highly similar for both the 
wild-type and the mutant allele, reconstitution experiments were performed[4]. For mutation 
I736G, synthetic constructs encompassing the 378 bp PCR product were generated. As shown 
for mutation R723G, defined mixtures of these plasmids were quantified (Fig. S1a, c). On 
average, the proportion of mutant fragments determined for the different mixtures were 0%, 
20.1±2.2%, 38.8±2.4%, 48±1.5%, 66.8±2.9%, 87.5±0.6% and 100%, respectively (n=3 
assays). Thus, the experimentally detected ratios were very similar to input ratios of the mixed 
allelic templates. The absence of the wild-type-specific fragment of 354 bp in the 100% 
mutant plasmid lane (Fig. S1a, lane 8) confirms complete digestion. An exemplary gel in 
Figure S1d shows restriction digests of PCR products derived from M. soleus of a healthy 
control individual (lane 4) and from one of the heterozygous patients (lane 6). 
 
Mutation V606M 
For amplification of the cDNA from the patient with the V606M mutation, the forward primer 
FEx16 606, located within exon 16, and the reverse primer RExon 16 II (Table S1), located at 
the splice junction between exons 16 and 17 were used. These primers specified a 287 bp 
PCR product with a cleavage site for NlaIII yielding two fragments of 267 bp and 20 bp. The 
V606M (c.1922G>A) mutation is caused by a G to A transition in exon 16, which creates an 
additional NlaIII cleavage site in the mutant sequence. Thus, NlaIII cleavage of a 
heterozygous 287 bp PCR product, containing both wild-type and mutated sequences, yields 
fragments of sizes 267 bp, 180 bp, 87 bp and 20 bp (Fig. S2a, b). 
The IOD/bp ratio of mutant-specific 180 bp fragment vs. the total IOD/bp value of wild-type-
specific 267 bp fragment plus the mutant-specific 180 bp fragment was used for determining 
the fraction of mutated MYH7-mRNA. The mutation-specific smaller 87 bp fragment was 
somewhat weaker on the gel, resulting in larger uncertainties of the IOD/ bp values. This was 
evident when calculating as internal control the ratio of the 87 bp fragment vs. the 180 bp 
fragment which was 0.85±0.17 instead of 1 as expected. The plasmid control indicates that the 
lower intensity of the band with 87 bp fragments is not due to incomplete digestion of the 
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PCR product, since complete digestion at all cleavage sites was found (Fig. S2a, lane 8). 
Therefore we exclusively used the 180 bp fragment for quantification analysis. 
A plasmid control for efficiency of PCR amplification and digestion of the products of both 
alleles was again performed as described above. Synthetic constructs containing the 287 bp 
PCR product were mixed in defined ratios and quantified by the same procedure as used for 
the transcript (Fig. S2a). The fractions of mutant obtained from the defined mixtures were 0%, 
19±4.1%, 34.2±7.5%, 47.7±0.9%, 68.7±1.8%, 87.9±1.9% and 100%, respectively (Fig. S2c, 
n=3 assays), which is very similar to the input ratios. Figure S2d shows as example restriction 
digests of PCR product derived from M. soleus of patient H5 (lanes 3,4).  
 
Mutation R719W 
The R719W (c2261C>T) mutation results from a C to T transition, which abolishes a MspI 
restriction site in the mutant sequence. The primers used for amplification of this mutation 
(Table S1) specify a 378 bp PCR product (Fig. S3). For the heterozygous patient the MspI 
digest produces two bands with wild-type-specific fragments of 146 bp and 123 bp, one band 
of 269 bp characteristic for the mutated allele, and one fragment of 109 bp from both wild-
type and mutant sequence (Fig. S3a, b). The fraction of mutated MYH7-mRNA was calculated 
based on the IOD/ bp value of the mutation-specific 269 bp fragment vs. the average of the 
IOD/ bp values of the two wild-type-specific fragments of 146 bp and 123 bp plus the IOD/ 
bp value of the 269 bp fragment. We used the average of the two wild-type specific fragments 
because they are equally abundant, the ratio of their IOD/ bp values was 0.99±0.07 in the 
analysis of the biopsy. 
The plasmid control with known mixtures of synthetic fragments containing the 378 bp PCR 
product yielded mutant fractions of 0%, 20.8±1.5%, 41.4±3.1%, 50.3±4.2%, 70.7±5.1%, 
95±8.4% and 100% (calculated from the ratio of the 269 bp fragment vs. the 109 bp fragment; 
n=2 assays; Fig. S3a, c). Thus, input and experimentally determined ratios were essentially 
the same. Note, that the additional bands visible in lanes 2-8 in Figure S3a arise from 
cleavage of the vector (plasmid pMA-T) containing multiple cleavage sites for MspI, as 
indicated by the manufacturer. Obviously, the fragments obtained from the 378 bp sequence 
digest are not influenced by the extra bands. 
 
Real-Time PCR (RT-qPCR) for the allelic discrimiation of MYH7 R723G- and wildtype-
mRNA 
RT-qPCR was performed using an ABI Prism 7000 platform. The cDNA synthesis was 
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carried out as described earlier for the standard method using the primers listed in Table S1. 
Primer and hybridization probes for the real-time assay specific for the MYH7 R723G 
mutation were synthesized on demand (Assays-by-Design Service, Applied Biosystems, 
Foster City, CA). The hybridization probes specific for the detection of either wild-type or 
mutant alleles were fluorescently labelled at the 5’ ends with VIC and 6-FAM, respectively, 
and with a non-fluorescent quencher at the 3’ end (Table S2). Since mutation discrimination is 
achieved by probes that differ at the position of the R723G (c.2273C>G) mutation, 
amplification can be performed using the identical primers for both assays [5] to exclude bias 
caused by unequal amplification efficacy. Labelling the TaqMan probes with different 
fluorophores allows detection of the two alleles in a single-tube analysis. Quantification of 
mutated fraction is performed by calculation of the wild-type to mutant allele ratio.  
Conditions for real-time PCR: a total volume of 50 µl reaction mixture contained 25µl of 
TaqMan 2x Universal PCR MasterMix (Applied Biosystems), 0.9 µMol/L of each primer, 
0.2 µMol/L of each probe, and 20µl of appropriate cDNA dilutions. PCR was run 2 minutes at 
50°C, 10 minutes at 95°C, followed by up to 80 cycles of denaturation for 15 seconds at 95°C 
and annealing/extension for 1 minute at 60°C. For recording and analysis of fluorescent 
signals SDS software was used (Applied Biosystems). Relative quantification of our assays 
was performed according to the delta-CT method [3]. 
To determine the efficiency of the reaction, from each cDNA sample 1:10 serial dilutions 
were generated in Tris buffer (pH 7.5). Each dilution was obtained by mixing solutions at 4oC 
for at least 30 minutes for equilibration. Efficiency was calculated using the formula E=10[-
1/slope] [2]. Figure S4a shows an example of a cDNA dilution series from which the standard 
curves for both wild-type and mutant cDNA in Figure S4b were generated. The amplification 
efficiencies calculated from the slope of the curves were 1.98 for wild-type and 2.03 for 
mutant (n=8 assays). Close agreement was expected because identical primers are used for the 
mutant and the wild-type allele. The ratios of mutated vs. wild-type transcript were 
determined using the delta CT method.  
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Supplementary Table S1:  
Summary of primer sequences used for restriction digest approach.  
 
  Primer name 
Primer 
sense 
Primer sequence (5’-->3’) 
MYH7 specific 
reverse transcription 
primer 
RTR719W   TGC CAG GTT GTC TTG TTC CG 
β-myosin mutations 
R723G  
(c.2273 C>G) 
R723G Mut F Forward 
CCA ACC GCA TCC TCT ACG GGG 
ACT TCC GGC AGA GGG AT 
719R Reverse 
CTT TTT GTA CTC CAT TCT GGC 
GAG CAC A 
I736T 
(c.2313 T>C) 
736F* Forward 
ACA AAG TCT CCA GGC GTG ATG 
GTC AAC C 
719R Reverse 
CTT TTT GTA CTC CAT TCT GGC 
GAG CAC A 
V606M 
(c.1922 G>A) 
FEx16 606 Forward 
TCC CCA AGG CCA CCG ACA TGA 
CCT TCA AGG CCA AGC TGT TT 
RExon 16 II Reverse 
CTT TGC CCT TCT CAA TAG GCG 
CAT CAG 
R719W 
(c.2261 C>T) 
719F Forward 
ACG AAG TCT CCA GGC GTG ATG 
GAC AAC C 
719R Reverse 
CTT TTT GTA CTC CAT TCT GGC 
GAG CAC A 
The bold (T) in forward primer 736F* and the bold (G) in forward primer R723G Mut F are 
the base changes introduced into the MYH7 sequence to generate an additional restriction site, 
respectively. 
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Supplementary Table S2:  
Primer and probe sequences used in allele-specific real-time PCR.  
 
  Primer sequence (5’-->3’) 
FHC-MYH7-723_F (forward primer) CCC CAA CCG CAT CCT CTA C 
FHC-MYH7-723_R (reverse primer) GGA TGG CCG CTG GGT 
FHC-MYH7 wild-type probe TCAGGATGCGATACCT (VIC) 
FHC-MYH7 mutant probe CAGGATGCCATACCT (6-FAM) 
Probes specific to the wild-type and mutant alleles are labelled 5’ with VIC and 6-FAM, 
respectively. Position of the mutation is indicated in bold and underlined. 
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Supplementary Fig. S1  
Relative quantification of MYH7-mRNA with mutation I736T in defined mixtures of plasmids 
and tissue samples. (a) 3.5% agarose gel with Hpy8I restriction fragments of the 378 bp PCR 
product generated from plasmid mixtures by amplification with the I736T primers. Lane L; 
equimolar DNA standard, lane B; blank; lane 1; undigested 378 bp PCR product. Lanes 2-8, 
restriction fragments of PCR products from defined mixtures of plasmids containing wild-
type and mutated sequence as shown above each lane. Note, that the absence of the 354 bp 
fragment in lane 8 indicates complete cleavage at all sites (b) Expected Hpy8I restriction 
fragments for I736T; the 24 bp fragment is not seen on the agarose gels owing to its small 
size. (c) Validation of restriction digest approach using defined mixtures of synthetic 
plasmids. Filled circles, experimentally determined percentage of mutated sequences plotted 
vs. percentage of mutated plasmids put into mixtures (n=3 assays, ± SD). Dashed line, 
expected line if input and measured values were identical. (d) Gel of restriction digest of PCR 
products from M. soleus biopsies. Lane 1, equimolar DNA standard; Lane 2, blank; Lanes 3 
and 5, undigested PCR product; Lane 4, digest of PCR product of control cDNA; Lane 6, 
restriction fragments of PCR product of heterozygous patient 
 
Supplementary Fig. S2  
Relative quantification of MYH7-mRNA fraction with mutation V606M in mixtures of 
plasmids and tissue samples. (a) Plasmid control experiment showing the 287 bp PCR product 
generated with the V606M primers, and the Nla III restriction fragments. Defined mixtures of 
plasmids, containing wild-type and mutant sequence, as indicated above lanes 2-8, were 
subjected to PCR and restriction digest. Lane L; equimolar DNA standard, lane B; blank, lane 
1; undigested 287 bp PCR product. Note, that the absence of the 287 bp fragment in lane 8 
indicates complete cleavage at all sites. Nla III restriction digest yields fragments as shown 
schematically in (b). The faster migrating 20 bp product is not seen on the gel. (c) Plot of 
experimentally observed percentage of mutated sequence vs. percentage of mutated sequences 
put into the different plasmid mixtures (filled circles). Dashed line, expected line if input and 
measured values were identical. (d) Restriction digests of PCR product from M. soleus of 
patient H5. Lanes 1 and 2, equimolar DNA standard; Lanes 3 and 4, restriction fragments of 
heterozygous patient’s PCR product  
 
Supplementary Fig. S3  
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Relative quantification of MYH7-mRNA with mutation R719W in defined mixtures of 
plasmids and tissue samples. (a) Agarose gel showing Msp I restriction fragments and the 378 
bp PCR product obtained in a plasmid control experiment by amplification of mutant and 
wild-type sequence with the R719W primers. Lane L; equimolar DNA standard, lane B; 
blank, lane 1; undigested 378 bp PCR product. Lanes 2-8; defined mixtures of plasmids 
containing wild-type and mutated sequence as shown above each lane, subjected to PCR and 
restriction digest. Note that the absence of a 269 bp fragment in lane 2 indicates complete 
cleavage at all sites. Additional bands in lanes 2-8, not expected from the digest of the 378 bp 
sequence, arise from cleavage of the vector which contains multiple cleavage sites for Msp I. 
(b) Schematic representation of the expected fragments. (c) Plot of percentage of mutated 
sequence experimentally observed vs. percentage of mutated sequences put into the different 
plasmid mixtures (filled circles). Dashed line, expected line if input and measured values were 
identical. (d) Restriction digest of PCR product obtained from the patients M. soleus biopsy. 
Lane 1, equimolar DNA standard; Lane 2, blank; Lanes 3 and 4, restriction fragments of PCR 
product of heterozygous patients 
 
Supplementary Fig. S4  
Validation of the RT-qPCR-method for the relative quantification of MYH7 R723G- and 
wildtype-mRNA. (a) Example for 1:10 dilution series of cDNA from cardiac tissue samples 
of patient H27. Plotted is the delta Rn vs. cycle number for mutant (red) and wild type (blue) 
cDNA. The curves correspond to the undiluted sample, the 1:10 dilution and the 1:100 
dilution (from left to right). (b) Standard curves of CT (threshold cycle) versus log of dilution 
factor derived from wild-type and mutant curves in (a)  
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